Hepatocellular carcinoma

What Is Hepatocellular Carcinoma?

Hepatocellular carcinoma is the most common form of primary liver cancer, arising directly from the hepatocytes, the main functional cells that make up the liver.

Hepatocellular carcinoma is the fifth most common cancer and the second leading cause of cancer related death worldwide, reflecting both its frequency and its typically aggressive clinical course.¹

Chronic viral hepatitis is the most important factor in hepatocellular carcinoma development, with chronic hepatitis B and hepatitis C infections together accounting for approximately eighty percent of cases worldwide.¹

Viral hepatitis is the most important factor in HCC development, with chronic hepatitis B and hepatitis C infections being the most common causes, accounting for approximately eighty percent of HCC cases worldwide.
National Center for Biotechnology Information

Symptoms

Early hepatocellular carcinoma often produces no noticeable symptoms, which is one reason regular surveillance is so important for patients at elevated risk.

As the disease progresses, symptoms such as abdominal pain, unexplained weight loss, loss of appetite, and swelling in the abdomen due to fluid accumulation may develop.

Yellowing of the skin and eyes, known as jaundice, along with fatigue and general weakness, can also occur as liver function becomes increasingly impaired by tumor growth.

Causes

Chronic hepatitis B infection alone was responsible for approximately three hundred sixty thousand hepatocellular carcinoma cases in 2018, accounting for fifty five percent of total cases worldwide, while chronic hepatitis C infection caused approximately one hundred sixty thousand cases.¹

Both viruses drive long term liver inflammation and scarring that can eventually progress to cirrhosis, a condition strongly associated with the later development of hepatocellular carcinoma.¹

The annual incidence of hepatocellular carcinoma among patients with cirrhosis caused by chronic hepatitis B or hepatitis C infection ranges from two to five percent, highlighting the importance of ongoing monitoring in this population.²

Risk Factors

Cirrhosis, elevated hepatitis B viral DNA levels, advancing age, male sex, and the body’s immune response against the hepatitis B virus are all recognized risk factors for hepatitis B related hepatocellular carcinoma.¹

A combination of obesity and diabetes substantially increases hepatocellular carcinoma risk in patients who are hepatitis B surface antigen positive, with research showing a dramatically elevated relative risk when both conditions are present together.¹

For patients co infected with both hepatitis B and hepatitis C, age over forty five years, cirrhosis, infection duration of five years or longer, and elevated alpha fetoprotein levels above twenty nanograms per milliliter are independent predictors of hepatocellular carcinoma development.²

Complications

Alpha fetoprotein is the main tumor marker used for hepatocellular carcinoma surveillance, and its complementary use alongside ultrasound imaging improves the overall effectiveness of monitoring in patients with cirrhosis.³

Following treatment, alpha fetoprotein levels can serve as a useful clinical prognostic marker, with patients whose levels remain elevated after initial treatment experiencing notably shorter overall survival compared to those whose levels normalize.⁴

Because hepatocellular carcinoma often develops silently within an already damaged liver, disease progression can significantly complicate treatment options and overall prognosis if not identified through regular surveillance.³

Treatment

Transarterial chemoembolization is the most common locoregional therapy used for hepatocellular carcinoma, particularly in patients being evaluated as liver transplant candidates.⁵

This procedure works by delivering chemotherapy directly into the blood vessels supplying the tumor while simultaneously blocking blood flow, concentrating treatment effect while limiting exposure to the rest of the body.⁵

Following treatment, alpha fetoprotein response can help predict complete tumor necrosis, providing clinicians with a practical way to assess how effectively a given treatment has worked.⁶

Prevention

Vaccination against hepatitis B represents one of the most effective long term strategies for reducing hepatocellular carcinoma risk on a population level.¹

Appropriate antiviral treatment for chronic hepatitis B or hepatitis C infection can significantly reduce the risk of progression to cirrhosis and subsequent hepatocellular carcinoma.¹

For patients with existing cirrhosis, regular surveillance combining alpha fetoprotein testing with ultrasound imaging supports earlier detection, when treatment options remain most effective.³

Why Visual Communication Matters for Hepatocellular Carcinoma

Explaining how chronic viral infection progresses through liver inflammation and cirrhosis toward cancer requires visuals that make this complex, multi stage process clear to patients and clinical audiences alike.

Pharmaceutical companies, hepatology practices, and patient education organizations rely on precise illustration and animation to explain hepatocellular carcinoma development and treatment.

• Illustrating the progression from viral hepatitis to cirrhosis to cancer
• Animating transarterial chemoembolization and other locoregional therapies
• Explaining the role of alpha fetoprotein in surveillance and monitoring
• Visualizing liver anatomy and tumor vascular supply
• Supporting patient education on hepatitis prevention and surveillance
• Creating training materials for hepatology and oncology clinicians

How Biotic Artlab Supports Hepatocellular Carcinoma Communication

We work with pharmaceutical companies, hepatology practices, and healthcare organizations to create scientifically accurate visuals that make hepatocellular carcinoma easier to understand.

• Custom 3D animations of liver cell biology and disease progression
• Detailed illustrations of transarterial chemoembolization procedures
• Mechanism of action animations for systemic and locoregional therapies
• Patient facing materials on surveillance and hepatitis prevention
• Clinical training content for hepatology and oncology teams
• Conference presentations and marketing visuals for liver cancer audiences

Frequently Asked Questions

What is the leading cause of hepatocellular carcinoma?

Chronic hepatitis B and hepatitis C infection together account for approximately eighty percent of cases worldwide.¹

What is alpha fetoprotein used for?

It is the main tumor marker used for surveillance and monitoring treatment response in hepatocellular carcinoma.³

What is transarterial chemoembolization?

It is a locoregional treatment that delivers chemotherapy directly into the tumor’s blood supply while blocking blood flow to the tumor.⁵

Who is at highest risk for hepatocellular carcinoma?

Patients with cirrhosis caused by chronic hepatitis B or hepatitis C infection face the highest annual risk.²

Can hepatocellular carcinoma be prevented?

Hepatitis B vaccination and antiviral treatment for chronic viral hepatitis are among the most effective prevention strategies.¹

Why is surveillance important for hepatocellular carcinoma?

Early disease often causes no symptoms, so regular monitoring with alpha fetoprotein and ultrasound supports earlier detection and better outcomes.³

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to hepatocellular carcinoma, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information. Risk Factors and Prevention of Viral Hepatitis Related Hepatocellular Carcinoma.
2. National Center for Biotechnology Information. Prevalence and Risk Factors of Hepatocellular Carcinoma in Patients Co-infected With Hepatitis B and Hepatitis C.
3. National Center for Biotechnology Information. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis.
4. National Center for Biotechnology Information. Prognostic Role of Alpha Fetoprotein in Patients With Hepatocellular Carcinoma Treated With Repeat Transarterial Chemoembolization.
5. National Center for Biotechnology Information. Alpha Fetoprotein Response After First Transarterial Chemoembolization and Complete Pathologic Response in Patients With Hepatocellular Cancer.
6. National Center for Biotechnology Information. Alpha Fetoprotein and AFP L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma After Tumor Ablation.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, or individualized advice from a qualified healthcare professional.